ArticleOpen forum infectious diseases2016
A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses.
Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Exploratory study on blood and urine transcriptomes for identifying miRNA biomarkers in pediatric febrile bacterial and viral infections.Scientific reports · 2026Article
- Harnessing the host response for precision infectious disease diagnosis.Clinical microbiology reviews · 2024Review
- Article
- Using machine learning to determine the time of exposure to infection by a respiratory pathogen.Scientific reports · 2023Article
- Genomic Signature in Evolutionary Biology: A Review.Biology · 2023Review
- Transcriptional Profiles Elucidate Differential Host Responses to Infection withJournal of fungi (Basel, Switzerland) · 2022Article
- Implications of Using Host Response-Based Molecular Diagnostics on the Management of Bacterial and Viral Infections: A Review.Frontiers in medicine · 2022Review
- A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study.The Lancet. Infectious diseases · 2021Article
- Dysregulated transcriptional responses to SARS-CoV-2 in the periphery.Nature communications · 2021Article
- Dysregulated transcriptional responses to SARS-CoV-2 in the periphery support novel diagnostic approaches.medRxiv : the preprint server for health sciences · 2020Article
- Clinical metagenomics.Nature reviews. Genetics · 2019Review
- A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection.Nature communications · 2018Article
- The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Respiratory research · 2018Review
- New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance.Annual review of medicine · 2018Review
- A miRNA Host Response Signature Accurately Discriminates Acute Respiratory Infection Etiologies.Frontiers in microbiology · 2018Article
- Fecal Host Transcriptomics for Non-Invasive Human Mucosal Immune Profiling: Proof of Concept inPathogens & immunity · 2018Article
- Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Review
- Nasopharyngeal Protein Biomarkers of Acute Respiratory Virus Infection.EBioMedicine · 2017Article
- The effective rate of influenza reassortment is limited during human infection.PLoS pathogens · 2017Article
- Transcriptomics in Human Challenge Models.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Early, presymptomatic intervention with oseltamivir (corresponding to the onset of a published host-based genomic signature of influenza infection) resulted in decreased overall influenza symptoms (aggregate symptom scores of 23.5 vs 46.3), more rapid resolution of clinical disease (20 hours earlier), reduced viral shedding (total median tissue culture infectious dose [TCID50] 7.4 vs 9.7), and significantly reduced expression of several inflammatory cytokines (interferon-γ, tumor necrosis factor-α, interleukin-6, and others). The host genomic response to influenza infection is robust and may provide the means for early detection, more timely therapeutic interventions, a meaningful reduction in clinical disease, and an effective molecular means to track response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.